文献速递前列腺增生与排尿功能障碍男科与性医学

西洛多辛单药治疗与西洛多辛联合他达拉非附加治疗在前列腺增生患者中的比较

Comparison of Silodosin Monotherapy vs Silodosin With Tadalafil Add-on Therapy in Patients With Benign Prostatic Hyperplasia.
PubMed 文献 · Urology · 2017-04-18

本研究分析了103例接受西洛多辛治疗至少4周后IPSS仍大于8分的LUTS/BPH患者,比较继续西洛多辛单药治疗(4.0 mg每日两次)与加用他达拉非(5.0 mg每日一次)治疗8周的疗效与安全性。结果显示,附加治疗组在IPSS、OABSS和Qmax改善方面均显著优于单药组,不良事件发生率无显著差异。作者认为他达拉非附加治疗可能对西洛多辛单药抵抗的LUTS/BPH患者有效。

要点

  • 西洛多辛单药抵抗的LUTS/BPH患者加用他达拉非后IPSS、OABSS和Qmax改善显著优于继续单药治疗。
  • 在合并膀胱过度活动症的患者中,附加治疗对IPSS储尿期症状、IPSS尿急症状和OABSS尿急症状的改善显著优于单药治疗。
  • 两组不良事件发生率无显著差异(附加治疗组5.7% vs 单药组2.0%,P=0.62)。

核心结论

  • 他达拉非附加治疗可能对西洛多辛单药治疗抵抗的LUTS/BPH患者有效。

研究设计与样本

  • 研究纳入2016年4月至2016年12月在Kori医院接受西洛多辛治疗至少4周后IPSS大于8分的LUTS/BPH患者103例。
  • 患者随后接受西洛多辛4.0 mg每日两次单药治疗(单药组)或西洛多辛4.0 mg每日两次联合他达拉非5.0 mg每日一次附加治疗(附加治疗组)8周。
  • 评估从基线至8周IPSS、OABSS、Qmax和残余尿量的平均变化及不良事件。

主要发现

  • 103例患者中101例(98.1%)能够继续药物治疗。
  • 附加治疗组IPSS改善显著大于单药组(-3.92 vs -1.24,P<.05)。
  • 附加治疗组OABSS改善显著大于单药组(-1.18 vs 0.10,P<.05)。
  • 附加治疗组Qmax改善显著大于单药组(1.09 vs -1.04,P<.05)。
  • 附加治疗组4例中3例(5.7%)发生不良事件,单药组1例(2.0%),两组无显著差异(P=.62)。

临床怎么用

  • 作者认为他达拉非附加治疗可能对西洛多辛单药治疗抵抗的LUTS/BPH患者有效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy and safety of add-on therapy with the phosphodiesterase type 5 inhibitor tadalafil for patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia (LUTS/BPH) treated with the α1-adrenoceptor blocker silodosin. MATERIALS AND METHODS: We analyzed 103 patients with LUTS/BPH with an International Prostate Symptom Score (IPSS) of >8 after ≥4 weeks of silodosin treatment from April 2016 through December 2016 at Kori Hospital. The patients subsequently received silodosin 4.0 mg twice daily (monotherapy group) or silodosin 4.0 mg twice daily plus tadalafil 5.0 mg once daily (add-on therapy group) for 8 weeks. We assessed adverse events and evaluated the mean change from baseline to 8 weeks in the IPSS, Overactive Bladder Symptom Score (OABSS), maximum urine flow rate (Qmax), and post-void residual urine volume. RESULTS: Of 103 patients, 101 (98.1%) could continue medical treatment. The IPSS, OABSS, and Qmax showed significantly greater improvement in the add-on therapy than in the monotherapy group (-3.92 vs -1.24, -1.18 vs 0.10, and 1.09 vs -1.04, respectively; all P <.05). Although 4 patients experienced adverse events (add-on therapy: n = 3, 5.7%; monotherapy: n = 1, 2.0%), no significant differences were observed (P = .62). Among patients with overactive bladder (n = 55), the IPSS storage symptom subscore, IPSS urgency subscore, and OABSS urgency subscore showed significantly greater improvement in the add-on therapy than in the monotherapy group (-2.23 vs 0.17, -0.88 vs 0.28, and -1.5 vs -0.48, respectively; all P <.05). CONCLUSION: Add-on therapy with tadalafil may be effective for patients with LUTS/BPH resistant to silodosin monotherapy.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Yoshida T, Kinoshita H, Shimada S, et al. Comparison of Silodosin Monotherapy vs Silodosin With Tadalafil Add-on Therapy in Patients With Benign Prostatic Hyperplasia. Urology. 2017. PMID: 28431996. doi:10.1016/j.urology.2017.04.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。